| Characteristic | Treatment with placebo (N = 10) | Treatment with PRO 140 | All subjects (N = 44) | ||
| 162 mg weekly (N = 11) | 324 mg biweekly (N = 12) | 324 mg weekly (N = 11) | |||
| Age (yrs) | 44.9 (32.3 to 51.6) | 40.0 (29.1 to 44.6) | 45.9 (31.0 to 59.6) | 41.1 (34.8 to 53.6) | 42.3 (29.1 to 59.6) |
| Sex (no. male/no. female) | 9/1 | 10/1 | 11/1 | 10/1 | 40/4 |
| Race (no. black/no. white/ no. other) | 3/7 | 5/6 | 5/7 | 4/7 | 17/27 |
| Weight (kg) | 82.3 (59.4 to 107) | 77.0 (59.3 to 94.4) | 88.3 (58.9 to 102) | 69.0 (60.8 to 83.6) | 79.1 (58.9 to 107) |
| CD4+ cell count, cells/µL | 410 (312 to 878) | 352 (307 to 611) | 493 (357 to 911) | 389 (341 to 638) | 410 (307 to 911) |
| HIV‐1 RNA level, log10 copies/mL | 4.09 (3.94 to 5.13) | 4.43 (3.92 to 4.97) | 4.60 (4.03 to 6.68) | 4.19 (3.61 to 4.77) | 4.40 (3.61 to 6.68) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.